GlassScriptPhysician profile
Tina Koval
NPI 1518495316
$4,881.53
in general payments reported to CMS, 2019-2025
35 companies · $358 in 2025
The $358 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,912 · 2022: $1,922 · 2023: $674 · 2024: $15.26 · 2025: $358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,319.54 | 2021-2025 | |
| Novo Nordisk INC | $585.44 | 2021-2023 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $465.48 | 2021-2023 | Mounjaro, Jardiance, Trulicity |
| Phathom Pharmaceuticals, INC. | $233.59 | 2025 | Voquezna |
| Pfizer INC. | $210.28 | 2021-2023 | |
| Amgen INC. | $199.21 | 2021-2024 | Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $186.00 | 2021-2023 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.95 | 2021-2023 | Tradjenta, Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $171.96 | 2021-2023 | Vaxneuvance, Pneumovax 23, Gardasil 9 |
| Novartis Pharmaceuticals Corporation | $169.07 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.35 | 2021-2023 | |
| Abbott Laboratories | $152.70 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $115.52 | 2021-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $83.14 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.25 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $69.04 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $67.33 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $60.74 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $40.03 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.61 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $35.86 | 2021 | |
| Astellas Pharma US INC | $26.03 | 2022-2023 | Veozah |
| Amarin Pharma, INC. | $25.20 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $24.59 | 2023 | Rexulti |
| Esperion Therapeutics, INC. | $21.88 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.16 | 2023 | |
| Boston Scientific Corporation | $19.66 | 2022 | |
| Dexcom, INC. | $19.10 | 2023 | Dexcom G6 Transmitter |
| Ultragenyx Pharmaceutical INC. | $17.98 | 2022 | |
| Endo Pharmaceuticals INC. | $17.50 | 2021 | |
| Dynavax Technologies Corporation | $17.45 | 2023 | Heplisav-B |
| Idorsia Pharmaceuticals US INC | $16.74 | 2023 | Quviviq |
| Ibsa Pharma INC. | $16.46 | 2023 | Tirosint, Licart |
| Radius Health, INC. | $16.39 | 2021 | |
| Seqirus USA INC | $15.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tina Koval listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.